AstraZeneca’s Promising Phase III Study on AZD0901 for Advanced Gastric Cancer

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca is conducting a Phase III study titled A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2. The study aims to evaluate the efficacy and safety of AZD0901 as a treatment for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing Claudin18.2, compared to standard therapies chosen by investigators.

The study tests AZD0901, an investigational drug administered intravenously, against various established chemotherapies and targeted therapies. AZD0901 is intended to provide a new treatment option for patients with specific cancer profiles.

This interventional study employs a randomized, parallel assignment model with single masking for outcomes assessors. The primary purpose is treatment, with participants divided into groups receiving either AZD0901 or investigator-chosen therapies.

The study began on March 4, 2024, with primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 12, 2025, indicating ongoing recruitment and study progress.

This study could significantly impact AstraZeneca’s market position by potentially introducing a novel treatment option, influencing investor sentiment positively. Competitors in the oncology space will be closely watching these developments.

The study is currently ongoing, with further details available on the ClinicalTrials portal.